Drug firm Dr Reddy's Laboratories today said it has received establishment inspection report (EIR) from the US health regulator for its two units at Medak district in Telangana.
In an earlier filing to the bourses on March 9, the drug firm had said it had received five observations from the US Food and Drug Administration (USFDA) for its API Hyderabad plant 3 at Medak district.
On March 16, the company intimated the bourses that it had been issued a Form 483 with four observations for its API Hyderabad plant 1 at Jinnaram Mandal, Medak district.
"...we have received an establishment inspection report (EIR) from the USFDA, for both of the above-referred facilities," Dr Reddy's said in a filing to BSE.
As per the USFDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.
Shares of Dr Reddy's Laboratories were today trading at Rs 2,300 per scrip on BSE, up 0.33 percent from its previous close.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
